FDA clears breast biopsy device

Article

Advanced Imaging Technologies has received marketing clearance from the FDA for a breast biopsy on its Avera Breast Imaging System. Unlike conventional ultrasound scanners, Avera uses diffractive, or "through-wave," ultrasound. The biopsy capability will

Advanced Imaging Technologies has received marketing clearance from the FDA for a breast biopsy on its Avera Breast Imaging System. Unlike conventional ultrasound scanners, Avera uses diffractive, or "through-wave," ultrasound. The biopsy capability will allow physicians to perform immediate biopsies on suspicious breast masses during an Avera imaging session, according to the company.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Leading Breast Radiologists Discuss Rise of Breast Cancer Incidence in Women Under 40
New Research Examines Radiation Risks with CT Exposure Prior to Pregnancy
Diagnostic Imaging’s Weekly Scan: August 31 — September 6
© 2025 MJH Life Sciences

All rights reserved.